Partnership Leverages Callan JMB's Federal Contract Experience, Cold Chain Infrastructure, and Strategic National Stockpile Relationships to Enable Immediate Deployment Readiness

SPRING BRANCH, TX, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ:CJMB), ("Callan JMB" or the "Company"), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced it has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech Inc. ("Attune"), a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline. Callan JMB will serve as independent third-party overseer of Attune 's manufacturing, quality assurance and control, and deployment operations.

Under the agreement, Callan JMB will provide comprehensive federal oversight services, including manufacturing quality assurance and independent batch record review, Biomedical Advanced Research and Development Authority ("BARDA") contract compliance, Food and Drug Administration ("FDA") audit readiness and mock inspections, milestone tracking, and federal reporting, supply chain governance and supplier qualification, and Strategic National Stockpile deployment coordination—positioning Attune 's pipeline for immediate federal deployment through Callan JMB's existing government infrastructure.

• No comments yet. Be the first to comment!